Alexion Pharmaceuticals to Present Data on Soliris(R) (Eculizumab) and PNH at the 2007 American Society of Hematology (ASH) Annual Meeting

Saturday, November 10, 2007 General News J E 4
CHESHIRE, Conn., Nov. 9 Alexion Pharmaceuticals,Inc. (Nasdaq: ALXN) today announced that data relating to paroxysmal nocturnalhemoglobinuria (PNH), as well as to Soliris(R) (eculizumab) as a treatment forpatients with PNH, have been published by the American Society of Hematology(ASH). Abstracts will be presented at the 2007 ASH annual meeting that isbeing held December 8 to 11, 2007 at the Georgia World Congress Center inAtlanta.

The following abstracts will be presented in a poster session on red cellregulation and disorders of production on Monday, December 10, 2007. Theabstracts and presentation information can be accessed at the links providedbelow.

The following abstract will be presented in an oral session on red cellregulation and disorders of production on Tuesday, December 11, 2007. Theabstract and presentation information can be accessed at the link providedbelow.-- "High Incidence of Progression to Chronic Renal Insufficiency in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)" Dr. Peter Hillmen et al. -- "Sustained Improvements in Transfusion Requirements, Fatigue and Thrombosis with Eculizumab Treatment in Paroxysmal Nocturnal Hemoglobinuria" Dr. Gerard Socie et al. -- "Disease.Related Symptoms Reported across a Broad Population of Patients with Paroxysmal Nocturnal Hemoglobinuria" Dr. Gabrielle Meyers et al.

SOURCE Alexion Pharmaceuticals, Inc.


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
New Data Presented on the Renessa(R) Treatment for...
Atlanta Falcons Players Visit Hospitalized Veteran...